Point-of-care testing is forecast to expand from US$13.4 billion in 2008 to over US$22.5 billion in 2013 and comprise 25% of the total in vitro diagnostics market. Growth has been driven in part due to the promise of speed, convenience, and improved patient outcomes that point of care testing can bring.

Drawing on key opinion leaders in this field, SMi's 7th Annual Point of Care Diagnostics: Market Adoption and Technology Trends will present an insight into the many challenges facing the industry and provide an unsurpassed opportunity for you to obtain information you need in order to remain competitive in this evolving market. Remember to book before 30th June and save £200, visit our website for more information.

The conference will examine critical issues including:

Markets & Commercial Strategies: Understanding the drivers and barriers to PoCT adoption and competing in the evolving worldwide POCT market

Reimbursement, Remuneration and Regulation: Updated regulatory guidance and cost effectiveness analyses

Technology & Connectivity: New technologies, personalised medicine and managing point-of-care

For more information contact Zain Philbey on +44 (0) 20 7827 6722
or Email : zphilbey@smi-online.co.uk

Personalised Medicine & POCT - Opportunities and Challenges 27th October 2010, Crowne Plaza - The City, London. In association with Personalised Medicine Partners and Integrated Medicines Limited Hosted by: Michael Stocum, Founder and Managing Director, Personalised Medicine Partners and Dr Eddie Blair, Managing Director, Integrated Medicines Limited